Bakker WA - Search Results

1

Phacilitate, Barcelona Vaccine Forum 2010: focus on correlates of protection against influenza.

Soethout EC, Bakker WA, van Dam RH, Rots NY, Boog CJ. Soethout EC, et al. Among authors: bakker wa. Hum Vaccin. 2010 Dec;6(12):964-5. doi: 10.4161/hv.6.12.13218. Epub 2010 Dec 1. Hum Vaccin. 2010. PMID: 21150272 No abstract available.

2

Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.

Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WA. Verdijk P, et al. Among authors: bakker wa. Vaccine. 2013 Nov 12;31(47):5531-6. doi: 10.1016/j.vaccine.2013.09.021. Epub 2013 Sep 21. Vaccine. 2013. PMID: 24063976 Clinical Trial.

3

Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.

Verdijk P, Rots NY, Bakker WA. Verdijk P, et al. Among authors: bakker wa. Expert Rev Vaccines. 2011 May;10(5):635-44. doi: 10.1586/erv.11.51. Expert Rev Vaccines. 2011. PMID: 21604984 Free article. Review.

4

Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.

Verdijk P, Rots NY, van Oijen MG, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WA. Verdijk P, et al. Among authors: bakker wa. Vaccine. 2014 Sep 3;32(39):4938-44. doi: 10.1016/j.vaccine.2014.07.029. Epub 2014 Jul 18. Vaccine. 2014. PMID: 25043278 Clinical Trial.

5

Comparison of initial feasibility of host cell lines for viral vaccine production.

Vlecken DH, Pelgrim RP, Ruminski S, Bakker WA, van der Pol LA. Vlecken DH, et al. Among authors: bakker wa. J Virol Methods. 2013 Oct;193(1):28-41. doi: 10.1016/j.jviromet.2013.04.020. Epub 2013 May 14. J Virol Methods. 2013. PMID: 23684847

6

Development of inactivated poliovirus vaccine from Sabin strains: A progress report.

Okayasu H, Sein C, Hamidi A, Bakker WA, Sutter RW. Okayasu H, et al. Among authors: bakker wa. Biologicals. 2016 Nov;44(6):581-587. doi: 10.1016/j.biologicals.2016.08.005. Epub 2016 Oct 5. Biologicals. 2016. PMID: 27720268 Review.

7

Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals.

Thomassen YE, van 't Oever AG, van Oijen MG, Wijffels RH, van der Pol LA, Bakker WA. Thomassen YE, et al. Among authors: bakker wa. PLoS One. 2013 Dec 12;8(12):e83374. doi: 10.1371/journal.pone.0083374. eCollection 2013. PLoS One. 2013. PMID: 24349497 Free PMC article.

8

Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines.

Westdijk J, Brugmans D, Martin J, van't Oever A, Bakker WA, Levels L, Kersten G. Westdijk J, et al. Among authors: bakker wa. Vaccine. 2011 Apr 18;29(18):3390-7. doi: 10.1016/j.vaccine.2011.02.085. Epub 2011 Mar 11. Vaccine. 2011. PMID: 21397718

9

sIPV process development for costs reduction.

Thomassen YE, Bakker WA. Thomassen YE, et al. Among authors: bakker wa. Vaccine. 2015 Aug 20;33(35):4307-12. doi: 10.1016/j.vaccine.2015.03.076. Epub 2015 Apr 6. Vaccine. 2015. PMID: 25858858

10

Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.

Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A, Kersten GF, van den Heuvel N, Hendriks JT, van der Pol LA. Bakker WA, et al. Vaccine. 2011 Sep 22;29(41):7188-96. doi: 10.1016/j.vaccine.2011.05.079. Epub 2011 Jun 7. Vaccine. 2011. PMID: 21651934

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters